成人生长激素缺乏症患者18个月生长激素替代治疗对骨密度影响的回顾性研究

IF 2.3 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Ya-Yin Shen, Jia-Ni Ma, Zi-Yu Ren, Jie Liu, Xin-Yi Zhou, Xue-Rui Xie, Wei Ren
{"title":"成人生长激素缺乏症患者18个月生长激素替代治疗对骨密度影响的回顾性研究","authors":"Ya-Yin Shen,&nbsp;Jia-Ni Ma,&nbsp;Zi-Yu Ren,&nbsp;Jie Liu,&nbsp;Xin-Yi Zhou,&nbsp;Xue-Rui Xie,&nbsp;Wei Ren","doi":"10.1155/2023/4988473","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The effect of physiological dose growth hormone (GH) replacement therapy on bone mineral density (BMD) in adults with growth hormone deficiency (GHD) is not well defined. We aimed to investigate the effects of 18 months of treatment with recombinant human growth hormone (rhGH) at physiological doses on BMD, body composition (BC), and quality of life (QoL).</p><p><strong>Methods: </strong>Sixty-eight patients diagnosed with adult growth hormone deficiency (AGHD) in our hospital were included in this retrospective study. All patients received individualized rhGH replacement to maintain normal serum insulin-like growth factor-1 (IGF-1) levels. BMD and BC measurements were performed by dual energy X-ray absorptiometry (DXA). Excluding those with incomplete follow-up data, we analyzed BMD in 68 patients, as well as BC and QoL in 36 of them.</p><p><strong>Results: </strong>Compared with the baseline, lumbar spine BMD decreased by 0.008 g/cm<sup>2</sup> (<i>P</i>=0.006) and increased by 0.011 g/cm<sup>2</sup> (<i>P</i>=0.045) at month 18, and total hip BMD decreased by 0.005 g/cm<sup>2</sup> (<i>P</i>=0.008) and did not change significantly from the baseline at month 18. The changes in BMD did not differ by sex, and the increase in BMD was more pronounced in patients with low <i>Z</i>-scores at the baseline (lumbar spine: <i>P</i>=0.005 and total hip: <i>P</i>=0.018). The percentage change from the baseline in BMD was greater for the lumbar spine than for the total hip (<i>P</i>=0.003). Lean body mass (LBM) increased significantly (<i>P</i>=0.012), total body fat ratio (TBF%) decreased significantly (<i>P</i>=0.011), visceral adipose tissue (VAT) decreased significantly (<i>P</i>=0.016), and QoL improved significantly (<i>P</i> < 0.001).</p><p><strong>Conclusions: </strong>Within 18 months of treatment, bone resorption manifested first, BMD decreased to a nadir at month 6, and then it increased. The increase in BMD was greater in the lumbar spine than in the hip, and the increase was more pronounced in patients with low BMD. Eighteen months of rhGH replacement therapy significantly improved lumbar spine BMD and improved BC and QoL.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081901/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effects of 18 Months of Growth Hormone Replacement Therapy on Bone Mineral Density in Patients with Adult Growth Hormone Deficiency: A Retrospective Study.\",\"authors\":\"Ya-Yin Shen,&nbsp;Jia-Ni Ma,&nbsp;Zi-Yu Ren,&nbsp;Jie Liu,&nbsp;Xin-Yi Zhou,&nbsp;Xue-Rui Xie,&nbsp;Wei Ren\",\"doi\":\"10.1155/2023/4988473\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The effect of physiological dose growth hormone (GH) replacement therapy on bone mineral density (BMD) in adults with growth hormone deficiency (GHD) is not well defined. We aimed to investigate the effects of 18 months of treatment with recombinant human growth hormone (rhGH) at physiological doses on BMD, body composition (BC), and quality of life (QoL).</p><p><strong>Methods: </strong>Sixty-eight patients diagnosed with adult growth hormone deficiency (AGHD) in our hospital were included in this retrospective study. All patients received individualized rhGH replacement to maintain normal serum insulin-like growth factor-1 (IGF-1) levels. BMD and BC measurements were performed by dual energy X-ray absorptiometry (DXA). Excluding those with incomplete follow-up data, we analyzed BMD in 68 patients, as well as BC and QoL in 36 of them.</p><p><strong>Results: </strong>Compared with the baseline, lumbar spine BMD decreased by 0.008 g/cm<sup>2</sup> (<i>P</i>=0.006) and increased by 0.011 g/cm<sup>2</sup> (<i>P</i>=0.045) at month 18, and total hip BMD decreased by 0.005 g/cm<sup>2</sup> (<i>P</i>=0.008) and did not change significantly from the baseline at month 18. The changes in BMD did not differ by sex, and the increase in BMD was more pronounced in patients with low <i>Z</i>-scores at the baseline (lumbar spine: <i>P</i>=0.005 and total hip: <i>P</i>=0.018). The percentage change from the baseline in BMD was greater for the lumbar spine than for the total hip (<i>P</i>=0.003). Lean body mass (LBM) increased significantly (<i>P</i>=0.012), total body fat ratio (TBF%) decreased significantly (<i>P</i>=0.011), visceral adipose tissue (VAT) decreased significantly (<i>P</i>=0.016), and QoL improved significantly (<i>P</i> < 0.001).</p><p><strong>Conclusions: </strong>Within 18 months of treatment, bone resorption manifested first, BMD decreased to a nadir at month 6, and then it increased. The increase in BMD was greater in the lumbar spine than in the hip, and the increase was more pronounced in patients with low BMD. Eighteen months of rhGH replacement therapy significantly improved lumbar spine BMD and improved BC and QoL.</p>\",\"PeriodicalId\":13966,\"journal\":{\"name\":\"International Journal of Endocrinology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081901/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Endocrinology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2023/4988473\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/4988473","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

目的:生理剂量生长激素(GH)替代疗法对生长激素缺乏症(GHD)成人骨密度(BMD)的影响尚不明确。我们的目的是研究重组人生长激素(rhGH)在生理剂量下治疗18个月对BMD、身体成分(BC)和生活质量(QoL)的影响。方法:对我院确诊为成人生长激素缺乏症(AGHD)的68例患者进行回顾性研究。所有患者接受个体化rhGH替代以维持正常的血清胰岛素样生长因子-1 (IGF-1)水平。采用双能x线吸收仪(DXA)测量骨密度和BC。排除随访数据不完整的患者,我们分析了68例患者的BMD,以及其中36例患者的BC和QoL。结果:与基线相比,第18个月腰椎骨密度下降0.008 g/cm2 (P=0.006),增加0.011 g/cm2 (P=0.045),全髋骨密度下降0.005 g/cm2 (P=0.008),与基线相比无显著变化。骨密度的变化没有性别差异,基线时z评分较低的患者骨密度的增加更为明显(腰椎:P=0.005,全髋关节:P=0.018)。与基线相比,腰椎骨密度的百分比变化大于全髋关节(P=0.003)。瘦体质量(LBM)显著升高(P=0.012),体脂比(TBF%)显著降低(P=0.011),内脏脂肪组织(VAT)显著降低(P=0.016),生活质量显著改善(P < 0.001)。结论:治疗18个月后以骨吸收为主,骨密度在治疗6个月时降至最低点,随后升高。骨密度的增加在腰椎比在髋部更大,并且在骨密度低的患者中增加更明显。18个月的rhGH替代治疗显著改善腰椎骨密度,改善BC和QoL。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Effects of 18 Months of Growth Hormone Replacement Therapy on Bone Mineral Density in Patients with Adult Growth Hormone Deficiency: A Retrospective Study.

Effects of 18 Months of Growth Hormone Replacement Therapy on Bone Mineral Density in Patients with Adult Growth Hormone Deficiency: A Retrospective Study.

Effects of 18 Months of Growth Hormone Replacement Therapy on Bone Mineral Density in Patients with Adult Growth Hormone Deficiency: A Retrospective Study.

Effects of 18 Months of Growth Hormone Replacement Therapy on Bone Mineral Density in Patients with Adult Growth Hormone Deficiency: A Retrospective Study.

Objective: The effect of physiological dose growth hormone (GH) replacement therapy on bone mineral density (BMD) in adults with growth hormone deficiency (GHD) is not well defined. We aimed to investigate the effects of 18 months of treatment with recombinant human growth hormone (rhGH) at physiological doses on BMD, body composition (BC), and quality of life (QoL).

Methods: Sixty-eight patients diagnosed with adult growth hormone deficiency (AGHD) in our hospital were included in this retrospective study. All patients received individualized rhGH replacement to maintain normal serum insulin-like growth factor-1 (IGF-1) levels. BMD and BC measurements were performed by dual energy X-ray absorptiometry (DXA). Excluding those with incomplete follow-up data, we analyzed BMD in 68 patients, as well as BC and QoL in 36 of them.

Results: Compared with the baseline, lumbar spine BMD decreased by 0.008 g/cm2 (P=0.006) and increased by 0.011 g/cm2 (P=0.045) at month 18, and total hip BMD decreased by 0.005 g/cm2 (P=0.008) and did not change significantly from the baseline at month 18. The changes in BMD did not differ by sex, and the increase in BMD was more pronounced in patients with low Z-scores at the baseline (lumbar spine: P=0.005 and total hip: P=0.018). The percentage change from the baseline in BMD was greater for the lumbar spine than for the total hip (P=0.003). Lean body mass (LBM) increased significantly (P=0.012), total body fat ratio (TBF%) decreased significantly (P=0.011), visceral adipose tissue (VAT) decreased significantly (P=0.016), and QoL improved significantly (P < 0.001).

Conclusions: Within 18 months of treatment, bone resorption manifested first, BMD decreased to a nadir at month 6, and then it increased. The increase in BMD was greater in the lumbar spine than in the hip, and the increase was more pronounced in patients with low BMD. Eighteen months of rhGH replacement therapy significantly improved lumbar spine BMD and improved BC and QoL.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International Journal of Endocrinology
International Journal of Endocrinology ENDOCRINOLOGY & METABOLISM-
CiteScore
5.20
自引率
0.00%
发文量
147
审稿时长
1 months
期刊介绍: International Journal of Endocrinology is a peer-reviewed, Open Access journal that provides a forum for scientists and clinicians working in basic and translational research. The journal publishes original research articles, review articles, and clinical studies that provide insights into the endocrine system and its associated diseases at a genomic, molecular, biochemical and cellular level.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信